BerandaNBY • NYSEAMERICAN
add
NovaBay Pharmaceuticals Inc
Tutup sebelumnya
$0,70
Rentang hari
$0,67 - $0,73
Rentang tahun
$0,36 - $9,08
Kapitalisasi pasar
3,52Â jt USD
Volume Rata-Rata
337,69Â rb
Rasio P/E
-
Hasil dividen
-
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 2,44Â jt | -1,61% |
Biaya operasional | 2,65Â jt | 12,46% |
Laba bersih | -1,21Â jt | 31,02% |
Margin laba bersih | -49,65 | 29,89% |
Penghasilan per saham | -0,59 | 95,41% |
EBITDA | -1,05Â jt | -53,58% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 776,00Â rb | -77,65% |
Total aset | 3,88Â jt | -69,83% |
Total liabilitas | 2,80Â jt | -51,76% |
Total ekuitas | 1,07 jt | — |
Saham yang beredar | 4,89 jt | — |
Harga terhadap nilai buku | 3,19 | — |
Tingkat pengembalian aset | -68,00% | — |
Tingkat pengembalian modal | -142,34% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -1,21Â jt | 31,02% |
Kas dari operasi | -2,06Â jt | -466,21% |
Kas dari investasi | -2,00Â rb | -100,00% |
Kas dari pembiayaan | 2,09Â jt | 462,05% |
Perubahan kas bersih | 26,00Â rb | 102,13% |
Arus kas bebas | -1,48Â jt | -433,66% |
Tentang
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.
and NeutroPhase, used in treatment of Necrotizing Fasciitis Wikipedia
Didirikan
2000
Kantor pusat
Situs
Karyawan
25
